Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00439868 | A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure | PHASE1 | COMPLETED | 33 | — | — | Feb 16, 2007 | Jun 8, 2007 | Aug 10, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment Group 1 | EXPERIMENTAL | Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks. |
| Treatment Group 2 | EXPERIMENTAL | Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. |
| Name | Type | Description |
|---|---|---|
| WellbutrinXL | DRUG | WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg. |
| placebo | DRUG | Matching placebo tablets to WELLBUTRIN XL. |
Inclusion Criteria: * Healthy males or females. * Non-smokers * Agree to remain in the clinic for the time defined in the protocol. * Normal ECG. Exclusion Criteria: * Any serious medical disorder or condition. * Any history of an endocrine disorder. * Any clinically significant laboratory abnorm...